Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omega-DEK in Childhood Apraxia of Speech
NCT07216001Phase 2Not yet recruiting
- Start
- Nov 2026
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Omega-DEK in Childhood apraxia of speech (CAS), intestinal lymphangiectasia (PIL), fat malabsorption syndrome. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
Omega-DEK
03
Conditions
Childhood apraxia of speech (CAS)intestinal lymphangiectasia (PIL)fat malabsorption syndrome
Beyond the preview
Go deeper on NCT07216001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07216001.